|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sha H, Zou Z, Xin K, Bian X, Cai X, Lu W,
Chen J, Chen G, Huang L, Blair AM, et al: Tumor-penetrating peptide
fused EGFR single-domain antibody enhances cancer drug penetration
into 3D multicellular spheroids and facilitates effective gastric
cancer therapy. J Control Release. 200:188–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Refaat A, Abd-Rabou A and Reda A: TRAIL
combinations: The new ‘trail’ for cancer therapy (Review). Oncol
Lett. 7:1327–1332. 2014.PubMed/NCBI
|
|
5
|
Foillard S, Jin ZH, Garanger E, Boturyn D,
Favrot MC, Coll JL and Dumy P: Synthesis and biological
characterisation of targeted pro-apoptotic peptide. Chembiochem.
9:2326–2332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ellerby HM, Arap W, Ellerby LM, Kain R,
Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E,
et al: Anti-cancer activity of targeted pro-apoptotic peptides. Nat
Med. 5:1032–1038. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marks AJ, Cooper MS, Anderson RJ, Orchard
KH, Hale G, North JM, Ganeshaguru K, Steele AJ, Mehta AB, Lowdell
MW, et al: Selective apoptotic killing of malignant hemopoietic
cells by antibody-targeted delivery of an amphipathic peptide.
Cancer Res. 65:2373–2377. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thornberry NA, Rosen A and Nicholson DW:
Control of apoptosis by proteases. Adv Pharmacol. 41:155–177. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thornberry NA and Lazebnik Y: Caspases:
Enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chu DS, Bocek MJ, Shi J, Ta A,
Ngambenjawong C, Rostomily RC and Pun SH: Multivalent display of
pendant pro-apoptotic peptides increases cytotoxic activity. J
Control Release. 205:155–161. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Javadpour MM, Juban MM, Lo WC, Bishop SM,
Alberty JB, Cowell SM, Becker CL and McLaughlin ML: De novo
antimicrobial peptides with low mammalian cell toxicity. J Med
Chem. 39:3107–3113. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hyun S, Lee S, Kim S, Jang S, Yu J and Lee
Y: Apoptosis inducing, conformationally constrained, dimeric
peptide analogs of KLA with submicromolar cell penetrating
abilities. Biomacromolecules. 15:3746–3752. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mai JC, Mi Z, Kim SH, Ng B and Robbins PD:
A proapoptotic peptide for the treatment of solid tumors. Cancer
Res. 61:7709–7712. 2001.PubMed/NCBI
|
|
14
|
Ma JL, Wang H, Wang YL, Luo YH and Liu CB:
Enhanced Peptide delivery into cells by using the synergistic
effects of a cell-penetrating Peptide and a chemical drug to alter
cell permeability. Mol Pharm. 12:2040–2048. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sugahara KN, Teesalu T, Karmali PP,
Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF and
Ruoslahti E: Tissue-penetrating delivery of compounds and
nanoparticles into tumors. Cancer Cell. 16:510–520. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sugahara KN, Teesalu T, Karmali PP,
Kotamraju VR, Agemy L, Greenwald DR and Ruoslahti E:
Coadministration of a tumor-penetrating peptide enhances the
efficacy of cancer drugs. Science. 328:1031–1035. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fu B, Long W, Zhang Y, Zhang A, Miao F,
Shen Y, Pan N, Gan G, Nie F, He Y, et al: Enhanced antitumor
effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain
metastatic breast cancer. Sci Rep. 5:80292015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bryde S and de Kroon AI: Nanocapsules of
platinum anticancer drugs: Development towards therapeutic use.
Future Med Chem. 1:1467–1480. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Xiao W, Zhang Y, Meza L, Tseng H,
Takada Y, Ames JB and Lam KS: Optimization of RGD-containing cyclic
peptides against αvβ3 integrin. Mol Cancer Ther. 15:232–240. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jain RK: The Eugene M. Landis Award
Lecture 1996. Delivery of molecular and cellular medicine to solid
tumors. Microcirculation. 4:1–23. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Milosevic MF, Fyles AW, Wong R, Pintilie
M, Kavanagh MC, Levin W, Manchul LA, Keane TJ and Hill RP:
Interstitial fluid pressure in cervical carcinoma: Within tumor
heterogeneity, and relation to oxygen tension. Cancer.
82:2418–2426. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Heldin CH, Rubin K, Pietras K and Ostman
A: High interstitial fluid pressure - an obstacle in cancer
therapy. Nat Rev Cancer. 4:806–813. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li R, Xie L, Zhu Z, Liu Q, Hu Y, Jiang X,
Yu L, Qian X, Guo W, Ding Y, et al: Reversion of pH-induced
physiological drug resistance: A novel function of copolymeric
nanoparticles. PLoS One. 6:e241722011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Netti PA, Berk DA, Swartz MA, Grodzinsky
AJ and Jain RK: Role of extracellular matrix assembly in
interstitial transport in solid tumors. Cancer Res. 60:2497–2503.
2000.PubMed/NCBI
|
|
25
|
Davies CL, Berk DA, Pluen A and Jain RK:
Comparison of IgG diffusion and extracellular matrix composition in
rhabdomyosarcomas grown in mice versus in vitro as spheroids
reveals the role of host stromal cells. Br J Cancer. 86:1639–1644.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brown E, McKee T, diTomaso E, Pluen A,
Seed B, Boucher Y and Jain RK: Dynamic imaging of collagen and its
modulation in tumors in vivo using second-harmonic generation. Nat
Med. 9:796–800. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma X, Jia J, Cao R, Wang X and Fei H:
Histidine-iridium (III) coordination-based peptide luminogenic
cyclization and cyclo-RGD peptides for cancer-cell targeting. J Am
Chem Soc. 136:17734–17737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Agemy L, Friedmann-Morvinski D, Kotamraju
VR, Roth L, Sugahara KN, Girard OM, Mattrey RF, Verma IM and
Ruoslahti E: Targeted nanoparticle enhanced proapoptotic peptide as
potential therapy for glioblastoma. Proc Natl Acad Sci USA.
108:17450–17455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alves ID, Carré M, Montero MP, Castano S,
Lecomte S, Marquant R, Lecorché P, Burlina F, Schatz C, Sagan S, et
al: A proapoptotic peptide conjugated to penetratin selectively
inhibits tumor cell growth. Biochim Biophys Acta. 1838:2087–2098.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen R, Braun GB, Luo X, Sugahara KN,
Teesalu T and Ruoslahti E: Application of a proapoptotic peptide to
intratumorally spreading cancer therapy. Cancer Res. 73:1352–1361.
2013. View Article : Google Scholar : PubMed/NCBI
|
